Some non‐factor products that work by facilitating the coagulation pathway (emicizumab)
and blocking the anticoagulant pathway (fitusiran, concizumab and marstacimab) for …

Over the last decade, the world of hemophilia has experienced an unprecedented
therapeutic advance, thanks to the progress in bioengineering technologies, leading to the …

Monitoring factor VIII (FVIII) activity has traditionally been complicated by discrepancies
between assays for the various sorts of FVIII molecules. The advent of novel nonfactor …

The classical goals of haemophilia A treatment are to prevent bleeds, minimise the risk of
long-term complications associated with joint damage, and improve quality of life by …

Accurate measurement of clotting factors VIII (FVIII) or IX (FIX) is vital for comprehensive
diagnosis and management of patients with hemophilia A or B. The one-stage activated …

Patients with severe hemophilia A (HA) have an increased risk of spontaneous and trauma‐
related bleeding because of a congenital absence of factor VIII (FVIII). Most severe HA …

Abstract Hemophilia A (HA) and B are inherited bleeding disorders caused by a deficiency
of factor VIII or factor IX, respectively. The current standard of care is the administration of …

Treatment of bleeding and thrombotic disorders is highly standardized and based on
evidence-based medicine guidelines. These evidence-based treatment schemes are well …

The unprecedented progress in addressing unmet needs in haemophilia care to date
includes developing several novel therapies that rebalance haemostasis by restoring …

BACKGROUND Postpartum hemorrhage is a leading cause of morbidity and mortality
worldwide, yet the associated early coagulopathy is not well defined. OBJECTIVE We …